Migraine disorders / ödem

Method of treating migraine headache without aura

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

TECHNICAL FIELD OF THE INVENTION The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and compositions for

Prodrug salts

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

TECHNICAL FIELD Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their

Prodrug salts

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

TECHNICAL FIELD Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their

Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

TECHNICAL FIELD OF THE INVENTION The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for

Method for pain relief using low power laser light

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Although it is often said that the common cold is the most prevalent disease among humankind, it is also true that chronic pain is an affliction that is almost as prevalent. Chronic headaches, muscle pain, joint pain, and the like are experienced by most individuals, and

Bumetanide analogs, compositions and methods of use

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, including derivatives, positional isomers, and prodrugs thereof, compositions comprising the same and methods of making and using the same. The present invention also relates

N,N-substituted cyclic amine derivatives

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

INDUSTRIAL FIELD OF THE APPLICATION The present invention relates to novel N,N-substituted cyclic amine compounds useful as a calcium antagonist, particularly as a nerve-selective calcium antagonist, specifically as an agent for treating and improving the diseases against which an inhibitory action

Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

CROSS REFERENCE TO RELATED APPLICATION The present invention is based on, and claims priority from 60/008,390, filed Dec. 8, 1995. BACKGROUND OF THE INVENTION This application is directed to inhibitors of nitric oxide synthase, and in particular substituted azacycle derivatives. Nitric Oxide in

Cyclic amidine analogs as inhibitors of nitric oxide synthase

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION This application is directed to inhibitors of Nitric oxide synthase, and in particular cyclic amidines. Nitric Oxide in Biology. The emergence of nitric oxide (NO), a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological

Aminoadamantane derivatives as therapeutic agents

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

Aminoadamantane derivatives as therapeutic agents

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

Aminoadamantane derivatives as therapeutic agents

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

Aromatic and heteroaromatic substituted amides

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF INVENTION The invention relates to a compound of formula ##STR1## wherein R.sup.1 is selected from the group consisting of hydrogen and fluoro. Compounds of formula 1, and pharmaceutically acceptable acid addition salts thereof, have been shown to mediate the Neurokinin 1 (NK-1, substance

PTEN inhibitor or Maxi-K channels opener

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

TECHNICAL FIELD The present invention relates to a new PTEN inhibitor or a new Maxi-K channels opener. More particularly, it relates to a PTEN inhibitor or new Maxi-K channels opener, which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula

PTEN inhibitor or Maxi-K channels opener

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

TECHNICAL FIELD The present invention relates to a new PTEN inhibitor or a new Maxi-K channels opener. More particularly, it relates to a PTEN inhibitor or new Maxi-K channels opener, which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula

migraine disorders/ödem

Method of treating migraine headache without aura

Prodrug salts

Prodrug salts

Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms

Method for pain relief using low power laser light

Bumetanide analogs, compositions and methods of use

N,N-substituted cyclic amine derivatives

Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase

Cyclic amidine analogs as inhibitors of nitric oxide synthase

Aminoadamantane derivatives as therapeutic agents

Aminoadamantane derivatives as therapeutic agents

Aminoadamantane derivatives as therapeutic agents

Aromatic and heteroaromatic substituted amides

PTEN inhibitor or Maxi-K channels opener

PTEN inhibitor or Maxi-K channels opener

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen